View Company Profile

Baxalta USA, Inc

Baxalta Incorporated (NYSE: BXLT) is a $6 billion global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology. Driven by passion to make a meaningful impact on patients’ lives, Baxalta’s broad and diverse pipeline includes biologics with novel mechanisms and advanced technology platforms such as gene therapy. The Baxalta Global Innovation and R&D Center is located in Cambridge, Massachusetts. Launched in 2015 following separation from Baxter International, Baxalta’s heritage in biopharmaceuticals spans decades. Baxalta’s therapies are available in more than 100 countries and it has advanced biological manufacturing operations across 12 facilities, including state-of-the-art recombinant production and plasma fractionation.  Headquartered in Northern Illinois, Baxalta employs 16,000 employees worldwide.

The Promise of the Baxalta Spark

Serving patients is our inspiration and we are passionate about improving their lives.

No matter what we do or where we work, we all strive for excellence on behalf of patients, caregivers and healthcare providers. We seek to understand their journey. Through our insights, we will deliver breakthrough therapies and personalized services.

We see a world with endless possibilities, where our imagination is inspired and harnessed with purpose. We embrace the bold and diverse ideas of one another and the world around us.

We build and empower agile, high-performing teams where we can be ourselves. We hold ourselves and each other accountable to the highest standards of ethics, integrity and performance. We take the time to celebrate success.

This is our spark at Baxalta. This is how we serve, with our hearts and our heads. This is how we make a meaningful difference so that our patients can dream big and experience life to the fullest.

At Baxalta, your life is our inspiration. Advertisement